Replies to post #49735 on Biotech Values

[DewDiligence]

The MF author is evidently confused about the disease settings. Tarceva failed in first-line NSCLC as an addition to standard chemo, but it succeeded as monotherapy in the second line.

[jbog]

wall,

I wrote to brian and he replied to me already.


On 7/16/07, Jbogd1 wrote:
nice story "but" the facts need a little cleaning. Both Iressa and Tarceva "failed" their 1st line studies.

Neither Iressa nor Tarceva are approved 1st line, so for Imclone to get close could be interesting. Tarceva and Iressa actually proved detrimental to 1st line patients.


thanks

==============================================================

Reply:
Hi,

I never claimed either are approved as first line treatments for NSCLC.

Brian